secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2023-05-31T23:59:59+00:00
Accession:  0001193125-23-157307
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Therapeutics prices $140M public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Gross proceeds of ~$140M from 22.99M shares at $2.00/share and 47.01M pre-funded warrants at $1.9999 each.
- Net proceeds estimated at $134.7M after underwriting discounts and expenses.
- Underwriters granted 30-day option to purchase up to 10.5M additional shares.
- Proceeds for general corporate purposes; existing cash plus offering expected to fund operations into 2026.
- Offering closed May 31 for shares and June 1 for warrants; Morgan Stanley and Wedbush lead.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523157307/0001193125-23-157307-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523157307/d476076d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-157307

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer